FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
Executive Summary
Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the drug and biologic review centers intact but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.
You may also be interested in...
As US FDA’s Principal Deputy Commissioner, Woodcock Focusing On Food Issues
Commissioner Robert Califf wants Janet Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.
Woodcock Focusing On Food Issues, Rather Than Drugs, As US FDA’s Principal Deputy Commissioner
Commissioner Robert Califf wants Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.
Gottlieb Promotes 'Team' Work For Product Reviews
US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.